Literature DB >> 6308674

Modulation of neuronal serotonin uptake by a putative endogenous ligand of imipramine recognition sites.

M L Barbaccia, O Gandolfi, D M Chuang, E Costa.   

Abstract

Imipramine inhibits the serotonin uptake by binding with high affinity to regulatory sites of this uptake located on axons that release serotonin. The number of imipramine recognition sites located on crude synaptic membrane preparations is reduced by two daily injections of imipramine or desmethylimipramine for 3 weeks. When the binding sites for [3H]imipramine are down-regulated the Vmax of the neuronal uptake of serotonin is increased. Moreover, in minces prepared from the brain hippocampus of rats receiving imipramine in a dose regimen that reduces the number of [3H]imipramine recognition sites, the efficiency of imipramine as a blocker of the serotonin uptake is diminished. Hence the high-affinity binding sites for [3H]imipramine may have a physiological role in modulation of serotonin reuptake. Probably this is mediated by an endogenous effector of these regulatory sites. A nonpeptidic constituent of rat brain capable of displacing [3H]imipramine from its high-affinity binding site and of inhibiting the serotonin uptake in a dose-related manner has been extracted and its partial purification is described.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6308674      PMCID: PMC384204          DOI: 10.1073/pnas.80.16.5134

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  The treatment of depressive states with G 22355 (imipramine hydrochloride).

Authors:  R KUHN
Journal:  Am J Psychiatry       Date:  1958-11       Impact factor: 18.112

2.  Desmethylimipramine-induced decrease in beta-adrenergic receptor binding in rat cerebral cortex.

Authors:  K Sarai; A Frazer; D Brunswick; J Mendels
Journal:  Biochem Pharmacol       Date:  1978       Impact factor: 5.858

3.  Development of beta-adrenergic receptor subsensitivity by antidepressants.

Authors:  S P Banerjee; L S Kung; S J Riggi; S K Chanda
Journal:  Nature       Date:  1977-08-04       Impact factor: 49.962

4.  Blockade of presynaptic alpha-receptors and of amine uptake in the rat brain by the antidepressant mianserine.

Authors:  P A Baumann; L Maître
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977-10       Impact factor: 3.000

Review 5.  Mode of action of antidepressant drugs.

Authors:  F Sulser; J Vetulani; P L Mobley
Journal:  Biochem Pharmacol       Date:  1978-02-01       Impact factor: 5.858

6.  Kinetics of serotonin accumulation into slices from rat brain: relationship to catecholamine uptake.

Authors:  E G Shaskan; S H Snyder
Journal:  J Pharmacol Exp Ther       Date:  1970-11       Impact factor: 4.030

7.  Active transport of 5-hydroxytryptamine by plasma membrane vesicles isolated from human blood platelets.

Authors:  G Rudnick
Journal:  J Biol Chem       Date:  1977-04-10       Impact factor: 5.157

8.  Specific tricyclic antidepressant binding sites in rat brain.

Authors:  R Raisman; M Briley; S Z Langer
Journal:  Nature       Date:  1979-09-13       Impact factor: 49.962

9.  High-affinity [3H]imipramine binding in rat hypothalamus: association with uptake of serotonin but not of norepinephrine.

Authors:  S Z Langer; C Moret; R Raisman; M L Dubocovich; M Briley
Journal:  Science       Date:  1980-12-05       Impact factor: 47.728

10.  Mechanism of imipramine inhibition of platelet 5-hydroxytryptamine transport.

Authors:  J Talvenheimo; P J Nelson; G Rudnick
Journal:  J Biol Chem       Date:  1979-06-10       Impact factor: 5.157

View more
  15 in total

1.  Reduced Bmax of [3H]-imipramine binding to platelets of depressed patients free of previous medication with 5HT uptake inhibitors.

Authors:  M F Poirier; C Benkelfat; H Loo; D Sechter; E Zarifian; A M Galzin; S Z Langer
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

Review 2.  Studies on the serotonin transporter in platelets.

Authors:  S Z Langer; A M Galzin
Journal:  Experientia       Date:  1988-02-15

Review 3.  Active drug metabolites. An overview of their relevance in clinical pharmacokinetics.

Authors:  S Garattini
Journal:  Clin Pharmacokinet       Date:  1985 May-Jun       Impact factor: 6.447

4.  Unaltered 5-HT- and desipramine-sensitive [3H]imipramine binding and [3H]5-HT uptake in rat brain after chronic imipramine and norzimeldine treatment.

Authors:  J Marcusson; I T Bäckström; S B Ross
Journal:  Psychopharmacology (Berl)       Date:  1988       Impact factor: 4.530

5.  Proceedings of the British Pharmacological Society. University of Dundee, 11th-14th September, 1984. Abstracts.

Authors: 
Journal:  Br J Pharmacol       Date:  1984-12       Impact factor: 8.739

6.  Interaction between 5-HT uptake inhibition and activation of 5-HT autoreceptors by exogenous agonists in rat cerebral cortex slices and synaptosomes.

Authors:  G Bonanno; M Raiteri
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-03       Impact factor: 3.000

7.  Inhibition of presynaptic alpha-2-adrenoceptor and opioid receptor agonist responses in the rat vas deferens by chronic imipramine treatment.

Authors:  R A Keith; A I Salama
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-04       Impact factor: 3.000

8.  Sodium dependent [3H]cocaine binding associated with dopamine uptake sites in the rat striatum and human putamen decrease after dopaminergic denervation and in Parkinsons disease.

Authors:  H Schoemaker; C Pimoule; S Arbilla; B Scatton; F Javoy-Agid; S Z Langer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-05       Impact factor: 3.000

9.  Tianeptine, a selective enhancer of serotonin uptake in rat brain.

Authors:  T Mennini; E Mocaer; S Garattini
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-11       Impact factor: 3.000

Review 10.  Platelets as a model for neurones?

Authors:  M Da Prada; A M Cesura; J M Launay; J G Richards
Journal:  Experientia       Date:  1988-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.